This topic does not allow articles, updates, and blog posts a long life. I posted with accuracy on it on February 26th, but most of that is now obsolete. Why?
The first reason is that, per Noah Welland and Sharon
LaFraniere in the February 27th New York Times, “F.D.A.
Clears Johnson & Johnson’s Shot, the Third Vaccine for U.S.” This American-Belgian product only requires
one application per person, and, as of the article’s date, its consortium “has
pledged to provide the United States with 100 million doses by the end of June,”
allowing, by July 31st, “more than enough shots to cover any
American adult who wants one.” Three
days later we heard from Elliot Hannon in Slate that “Merck Will Reportedly
Start Manufacturing Johnson & Johnson Coronavirus Vaccine,” including
sequestering “two facilities,” one of which will be dedicated to making the
drug, with people at the other providing ““fill-finish” services, the last
stage of the production process during which the vaccine substance is placed in
vials and packaged for distribution.”
This kind of cooperation is exactly what seemed to be missing in
December and January, and will make a huge difference in both quality and
saving of lives. A noble move.
The result of these two news items, written by Sheryl Gay
Stolberg et al. in The New York Times, also on March 2nd, was
that “Biden Vows Enough Vaccine ‘for Every Adult American’ by End of May.” The president Joe, knowing what he did about the
supply of the Pfizer-BioNTech and Moderna products as well as the new one, made
what then looked like an aggressive statement or stretch objective but, in the
time since, has seemed increasingly realistic.
The first two vaccine manufacturers “pledged last month to deliver
together enough to cover 200 million Americans by that date,” and the U.S. has
committed to buy 600 million doses from these two companies alone.
Almost immediately after it was approved, the Johnson &
Johnson vaccine got into a controversy.
The Moderna and Pfizer-BioNTech drugs were rated at 94 and 95 percent
“efficacy,” whereas Johnson & Johnson’s came in at only 72 percent. As a result, probably also due to this
product’s requiring only one dose, people started saying it was inferior. Not so, said Hilda Bastian in a well-documented
seven-plus-page March 7th exposition in The Atlantic. Bastian’s main points were that first, the
American-approved drugs are “essentially perfect when it comes to preventing
the gravest outcomes,” with “zero cases of hospitalization or death in clinical
trials for all (three) of these vaccines” (italics hers); second, the
products do vary in “preventing illness” and frequency of “adverse reactions”;
third, the rates of bad outcomes have been so tiny that in some cases adding
only one infected test subject would have dramatically changed that vaccine’s
published numbers; and fourth, despite failure
rates being microscopic for all of them we cannot be assured that will continue
forever, but the three are all superb.
Two other recent articles were noteworthy. In “The Pandemic Economy and the Rise of the
‘Noxious Contract,’” in the March 9th New York Times, David
Grusky discussed how we could compensate people choosing to work in dangerous
settings. With the federal government’s Occupational
Safety and Health Administration (OSHA) almost invisible, many environments,
perhaps sources of the majority of the American total of 29.6 million
coronavirus cases so far, have been unacceptably risky. Biden is working to fix that through the
Labor Department and by “trying to ensure that workers who turn down
health-jeopardizing employment can still qualify for unemployment insurance,” and
Grusky suggested other measures, particularly a “new G.I. Bill” allowing
workers in infection-hazardous jobs military veteran’s benefits and subsidized
housing qualification. Katherine J. Wu’s
“You’re Not Fully Vaccinated the Day of Your Last Dose” (The Atlantic,
March 17th) reminded us, backed up with a description of how
vaccines work, that two weeks need to elapse after that.
What are the latest American pandemic statistics? On the New York Times website for
March 17th, the 7-day averages of daily new cases, daily deaths, and number of
people hospitalized were 55,001, 1,260, and 41,275 respectively. Twelve percent of Americans have now been
fully vaccinated, with another 11% having received one dose and needing
another. As of yesterday, the 7-day
average of people getting vaccines each day was 2,503,771. Compared with the worst overall day of the
pandemic, January 9th, the four average numbers above are, in order,
down 78%, down 60%, down 70%, and up 611%.
Here is a map, rather changed since the last one I posted, of average new
daily cases by county, with those in white showing none, those with the lightest
color otherwise less than 10 per day per 100,000 population, and the most
intense over 250 per 100,000:
These figures show that we are doing the Covid-stopping job
in all respects. As long as we stay the
course with getting vaccinated, practicing social distancing, and wearing
masks, we will most likely be out of this by early summer. Let’s get there!
No comments:
Post a Comment